Novo Nordisk Halts Two More Trials of Experimental Cardiovascular Drug Ziltivekimab

MT Newswires · 1d ago
11:32 PM EDT, 09/07/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) stopped two additional clinical studies for its experimental heart failure treatment, ziltivekimab, Reuters reported Monday, citing a company spokesperson. The Danish drugmaker called off the trials ahead of schedule after an independent committee found a "low likelihood" that the results would differ from an earlier late-stage trial that showed the drug failed to reduce the risk of major adverse cardiovascular events compared with placebo. Amid the decision, the company intends to continue the trial of ziltivekimab in patients recovering from ⁠a heart attack. Results of this study are expected within the first half of 2027. Novo Nordisk did not immediately respond to a request for comment from MT Newswires.